Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5622 | 1532 | 30.8 | 56% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1294 | 8163 | FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CONFLICT OF INTEREST | Author keyword | 61 | 32% | 10% | 160 |
2 | CONFLICTS OF INTEREST | Author keyword | 16 | 25% | 4% | 54 |
3 | DRUG SAMPLES | Author keyword | 15 | 88% | 0% | 7 |
4 | EDITORIAL ETHICS | Author keyword | 15 | 88% | 0% | 7 |
5 | EDMOND J SAFRA ETH | Address | 14 | 42% | 2% | 26 |
6 | DRUG INDUSTRY | Author keyword | 10 | 24% | 2% | 35 |
7 | PHARMACEUTICAL REPRESENTATIVES | Author keyword | 8 | 75% | 0% | 6 |
8 | PHARMACEUTICAL PROMOTION | Author keyword | 6 | 53% | 1% | 8 |
9 | COMMERCIAL BIAS | Author keyword | 6 | 100% | 0% | 4 |
10 | DRUG PROMOTION | Author keyword | 5 | 50% | 0% | 7 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CONFLICT OF INTEREST | 61 | 32% | 10% | 160 | Search CONFLICT+OF+INTEREST | Search CONFLICT+OF+INTEREST |
2 | CONFLICTS OF INTEREST | 16 | 25% | 4% | 54 | Search CONFLICTS+OF+INTEREST | Search CONFLICTS+OF+INTEREST |
3 | DRUG SAMPLES | 15 | 88% | 0% | 7 | Search DRUG+SAMPLES | Search DRUG+SAMPLES |
4 | EDITORIAL ETHICS | 15 | 88% | 0% | 7 | Search EDITORIAL+ETHICS | Search EDITORIAL+ETHICS |
5 | DRUG INDUSTRY | 10 | 24% | 2% | 35 | Search DRUG+INDUSTRY | Search DRUG+INDUSTRY |
6 | PHARMACEUTICAL REPRESENTATIVES | 8 | 75% | 0% | 6 | Search PHARMACEUTICAL+REPRESENTATIVES | Search PHARMACEUTICAL+REPRESENTATIVES |
7 | PHARMACEUTICAL PROMOTION | 6 | 53% | 1% | 8 | Search PHARMACEUTICAL+PROMOTION | Search PHARMACEUTICAL+PROMOTION |
8 | COMMERCIAL BIAS | 6 | 100% | 0% | 4 | Search COMMERCIAL+BIAS | Search COMMERCIAL+BIAS |
9 | DRUG PROMOTION | 5 | 50% | 0% | 7 | Search DRUG+PROMOTION | Search DRUG+PROMOTION |
10 | GHOSTWRITING | 4 | 47% | 0% | 7 | Search GHOSTWRITING | Search GHOSTWRITING |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | DRUG COMPANIES | 74 | 64% | 5% | 72 |
2 | CONFLICTS OF INTEREST | 70 | 32% | 12% | 184 |
3 | GIFTS | 68 | 50% | 6% | 98 |
4 | PHARMACEUTICAL INDUSTRY | 46 | 19% | 14% | 218 |
5 | INTEREST POLICIES | 33 | 83% | 1% | 19 |
6 | PHARMACEUTICAL ADVERTISEMENTS | 25 | 62% | 2% | 26 |
7 | PHARMACEUTICAL SALES REPRESENTATIVES | 25 | 71% | 1% | 20 |
8 | REPRESENTATIVES | 24 | 24% | 6% | 89 |
9 | FREE LUNCH | 22 | 60% | 2% | 24 |
10 | SALES REPRESENTATIVES | 21 | 51% | 2% | 30 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Physicians and the pharmaceutical industry - Is a gift ever just a gift? | 2000 | 640 | 39 | 95% |
Scope and impact of financial conflicts of interest in biomedical research - A systematic review | 2003 | 782 | 55 | 60% |
Industry sponsorship and research outcome | 2012 | 43 | 112 | 52% |
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review | 2010 | 45 | 12 | 67% |
Industry Relationships Among Academic Institutional Review Board Members Changes From 2005 Through 2014 | 2015 | 1 | 14 | 93% |
The Impact of Disclosing Financial Ties in Research and Clinical Care A Systematic Review | 2010 | 28 | 35 | 83% |
Conflict of Interest in Clinical Practice Guideline Development: A Systematic Review | 2011 | 25 | 29 | 62% |
Industry sponsorship and selection of comparators in randomized clinical trials | 2010 | 40 | 17 | 59% |
Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature | 2011 | 16 | 24 | 83% |
Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments | 2011 | 42 | 57 | 35% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | EDMOND J SAFRA ETH | 14 | 42% | 1.7% | 26 |
2 | GLOBAL MED WRITING | 3 | 100% | 0.2% | 3 |
3 | MED PROFESS | 2 | 23% | 0.6% | 9 |
4 | HADASSAH COMMUNITY MED PUBL HLTH | 2 | 43% | 0.2% | 3 |
5 | DBHSR | 1 | 100% | 0.1% | 2 |
6 | P IDENTIAL OFF | 1 | 50% | 0.1% | 2 |
7 | PHOEBE R BERMAN ETH | 1 | 100% | 0.1% | 2 |
8 | A ALFRED TAUBMAN HLTH SCI LIB | 1 | 40% | 0.1% | 2 |
9 | REGULATORY AFFAIRS PROGRAM | 1 | 40% | 0.1% | 2 |
10 | AAFP | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000165157 | DIRECT TO CONSUMER ADVERTISING//DTCA//DTC ADVERTISING |
2 | 0.0000155901 | PUBLICATION RATE//MEETING ABSTRACTS//PUBLICATION BIAS |
3 | 0.0000120843 | NATURE INDEX//DIMENSIONS OF UNCERTAINTY//BIODIVERSITY SCIENCE |
4 | 0.0000104388 | RESEARCH MISCONDUCT//RESPONSIBLE CONDUCT OF RESEARCH//RESEARCH INTEGRITY |
5 | 0.0000082102 | IMPROPER PRACTICE//COMMUNICATION OF CLINICAL RESULTS//DISCOVERY GRANTS PROGRAM |
6 | 0.0000076190 | PHARMACEUTICALISATION//CRHAM//CORPORATE BIAS |
7 | 0.0000070833 | ACADEMIC DETAILING//DRUG UTILIZATION REVIEW//ADVANCED PULMONARY DISEASE |
8 | 0.0000057622 | PRESCRIBING INDICATORS//PRESCRIBING COSTS//FUNDHOLDING |
9 | 0.0000049775 | CONSORT//OTTAWA METHODS//REPORTING QUALITY |
10 | 0.0000047910 | INDUCTIVE RISK//VALUES IN SCIENCE//SCIENCE AND VALUES |